Podcasts about tetra discovery partners

On this week’s Tech Nation, cognitive scientist Maryanne Wolf and her book: “Reader, Come Home: The Reading Brain in a Digital World”. Then on Tech Nation Health, neuroscientist Dr. Mark Gurney, CEO of Tetra Discovery Partners, talks treatments for such challenges as Fragile X Syndrome, Alzheimer’s disease, and traumatic brain injury.

On this week’s Tech Nation, cognitive scientist Maryanne Wolf and her book: “Reader, Come Home: The Reading Brain in a Digital World”. Then on Tech Nation Health, neuroscientist Dr. Mark Gurney, CEO of Tetra Discovery Partners, talks treatments for such challenges as Fragile X Syndrome, Alzheimer’s disease, and traumatic brain injury.

On this week’s Tech Nation Health, neuroscientist Dr. Mark Gurney, CEO of Tetra Discovery Partners, talks treatments for such challenges as Fragile X Syndrome, Alzheimer’s disease, and traumatic brain injury.

On this week’s Tech Nation, cognitive scientist Maryanne Wolf and her book: “Reader, Come Home: The Reading Brain in a Digital World”. Then on Tech Nation Health, neuroscientist Dr. Mark Gurney, CEO of Tetra Discovery Partners, talks treatments for such challenges as Fragile X Syndrome, Alzheimer’s disease, and traumatic brain injury.

On this week’s Tech Nation Health, neuroscientist Dr. Mark Gurney, CEO of Tetra Discovery Partners, talks treatments for such challenges as Fragile X Syndrome, Alzheimer’s disease, and traumatic brain injury.

On this weeks Tech Nation, cognitive scientist Maryanne Wolf and her book, "Reader,Come Home:The Reading Brain In A Digital World" Then on Tech Nation Health, neuroscientist Dr Mark Gurney, CEO of Tetra Discovery Partners, talks treatments for such challenges as Fragile X Syndrome, Alzheimers and traumatic brain injury

Fragile X Syndrome is a rare developmental disorder and the most common cause of inherited intellectual disability. Tetra Discovery Partners, building on research about the role the enzyme PDE4 plays in the disease, is developing an experimental drug to inhibit its activity. We spoke to Mark Gurney, chairman and CEO of Tetra Discovery Partners, about Fragile X, the potential of its PDE4 inhibitor, and why this drug may have therapeutic benefit in a range of neurodegenerative diseases.